NDC42291-0439-30: EMTRICITABINE AND TENOFOVIR TABL.
EMTRICITABINE AND TENOFOVIR TABL. Key specifications include protective_storage_feature: CONTROLLED ROOM TEMPERATURE, part_name_assigned_by_controlling_agency: EMTRICITABINE/TENFOVIR (200MG/300MG) TABS 30S. This part is cataloged in the U.S.
Government catalog under NSN 6505-01-618-5356, indicating validated use in U.S. government and defense logistics supply chains. Available through authorized enterprise resellers and TPM (Third Party Maintenance) channels.
Verify compatibility with your specific system configuration before ordering.
| protective_storage_feature | CONTROLLED ROOM TEMPERATURE |
| part_name_assigned_by_controlling_agency | EMTRICITABINE/TENFOVIR (200MG/300MG) TABS 30S |
| NSN | 6505-01-618-5356 |
| SPECIAL FEATURES | 200MG EMTRICITABINE AND 300MG OF TENOFOVIR DISOPROXIL FUMARATE; 30 TABLETS PER BOTTLE; TAKEN ORALLY; COMBINATION OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE IS INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS (SUCH AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS OR PROTEASE INHIBITORS) FOR THE TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER; ALSO APPROVED FOR USE IN COMBINATION WITH SAFER SEX PRACTICES FOR PRE-EXPOSURE PROPHYLAXIS (PREP), TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 INFECTION IN ADULTS AT HIGH RISK |
| PROTECTIVE STORAGE FEATURE | CONTROLLED ROOM TEMPERATURE |
| PART NAME ASSIGNED BY CONTROLLING AGENCY | EMTRICITABINE/TENFOVIR (200MG/300MG) TABS 30S |